Subscribe
Sign in
Home
Work with us / Advertise
CensHERship
FutureFemHealth Pro
Partners and contributors
Archive
About
Latest
Top
Discussions
Reimbursement has moved up the women’s health agenda. Here’s why.
Founders and investors are thinking about who pays much earlier.
3 hrs ago
•
Anna O'Sullivan
12
Women’s health companies urged to weigh in on US Medicare payment changes
Advocates say the industry needs to make its voice heard
5 hrs ago
•
Anna O'Sullivan
Channel Medsystems raises $30m to expand heavy menstrual bleeding treatment
US medtech will accelerate commercial rollout of its non-hormonal Cerene treatment
Aug 21
•
Anna O'Sullivan
1
💌 Issue 159: $275m osteoporosis bet | FemTech & the NHS | New menopause drug data | Fertility reimbursement
+ lots more in the weekly briefing on the global women's health market
Aug 19
•
Anna O'Sullivan
14
Largest study to date maps how female testosterone levels change with age
Findings show testosterone declines gradually with age - rather than dropping off around menopause
Aug 19
•
Anna O'Sullivan
2
1
Is getting FemTech into the NHS solely an NHS problem?
A new Parliamentary briefing puts some of the responsibility back on the sector
Aug 18
•
Anna O'Sullivan
What happened to the women’s health market for women 65+?
Few companies have built specifically for older women. But that doesn't mean the market isn't emerging.
Aug 13
•
Anna O'Sullivan
23
1
💌 Issue 158: Clair Health + Mayo Clinic | $58M women’s health fund | HRT use doubles
+ lots more in the weekly briefing on the global women's health market
Aug 12
•
Anna O'Sullivan
18
The Women's Health Innovation Map: Why ecosystems matter beyond capital
A companion read to the Women's Health Innovation Map, curated by Anastasiya Markvarde.
Aug 12
•
Anna O'Sullivan
and
Anastasiya Markvarde
11
1
3
Clair Health joins Mayo Clinic programme to build clinical evidence behind hormone wearable
After attracting attention - and debate - for its approach to continuous hormone monitoring, Clair is embarking on a multi-year clinical validation…
Aug 11
•
Anna O'Sullivan
5
3
3
💌 Issue 157: Oura + Maven fertility study | $200M Yarrow deal | Pregnancy hypertension up 73%
+ lots more in the weekly briefing on the global women's health market
Aug 5
•
Anna O'Sullivan
28
1
Before IVF: the emerging market for a shorter path to pregnancy
From at-home diagnostics and wearables to fertility optimisation and lower-intervention treatments, a new layer of fertility care is emerging before…
Aug 4
•
Anna O'Sullivan
22
4
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts